Objective: To investigate the effects of perilla extract on urinary symptoms in spontaneously hypertensive rats as a model of spontaneous overactive bladder. Methods: Spontaneously hypertensive rats were randomly divided into two groups and fed either a control diet or a perilla extract-containing diet. Cystometry, gene expression and histological analyses were carried out to evaluate the effects of perilla extract after 2-week feeding of either the control or the perilla extract diet. The expression of inflammation-related genes in the human urothelial cell line HT-1376 and the normal human bladder epithelial cell was measured after the treatment with perillaldehyde, the main component of perilla extract, or perillic acid, the final metabolite of perillaldehyde. Results: A significant 27% increase in the micturition interval and decreased expression of nerve growth factor, tumor necrosis factor-a, interleukin-1b and transient receptor potential V1 were observed in the perilla group compared with the control group. The level of uroplakin 3A was 40% higher in the perilla group than in the control group. The urothelium in the control group was thin or defective, but it was almost completely intact in the perilla group. Perillaldehyde and perillic acid suppressed the induction of nerve growth factor and tumor necrosis factor-a by interleukin-1b in HT-1376 and normal human bladder epithelial cells. Conclusions: The present findings suggest that perilla extract improves frequent urination, and this improvement seems to be mediated, at least in part, by enhancement of the urothelial presence and by the anti-inflammatory effects of perilla.
Introduction
Urinary disorders are important clinical problems, because they disrupt the quality of life of elderly individuals. 1 In particular, OAB is a well-known syndrome characterized by frequent urination, urinary incontinence and urgency. The prevalence rate of OAB is estimated at 12.4% for people aged >40 years in Japan.
1 Furthermore, as the incidence rate of OAB is rapidly increasing with the aging of the population worldwide, novel treatments are required. 1 Although the mechanism of OAB has yet to be clearly defined, inflammation and TRP channels in the bladder could be related to OAB. Chronic inflammation is histopathologically apparent in the urothelium and suburothelium in approximately 60% of patients with OAB. 2 Furthermore, a significant increase in mast cell infiltration in the bladder was observed in patients with OAB compared with healthy individuals. 3 Bladder inflammation impairs the barrier function of the urothelium, 4,5 and increases the expression of TRPV1. 6 The role of TRPV1 in regulating bladder function has been shown using TRPV1 knockout mice. 7 Similarly, a high expression of TRPV1 8 and an elevated reaction to capsaicin, a TRPV1 agonist, have been observed in the bladders of patients with OAB.
9
Perilla is an aromatic plant that is traditionally used as a medicinal herb in Asia. In Japan, perilla has a wide range of uses, from flavoring food to preventing food poisoning. 10 From a medical perspective, perilla has been used for its anti-oxidant, anti-inflammatory and antiallergy effects. 11, 12 However, the effectiveness of perilla in the treatment of OAB has not yet been evaluated. Therefore, the aim of the present study was to investigate the effects of perilla on the urinary symptoms of SHRs, an animal model known to have spontaneous OAB. 13 
Methods

Animals
Female SHRs (SHR/hos, n = 35, 210-245 g, 38-42 weeks old; SLC, Shizuoka, Japan) were used. All animals were housed under a 12-h light cycle. Animals were housed in our animal facility for at least 1 week before any experimental procedure, and fed a standard rodent pellet diet (CE-2; CLEA, Tokyo, Japan) and water ad libitum. All animal experiments were carried out in the Experimental Animal Facility of Kao Tochigi Institute, and the study was approved by the Animal Care Committee of Kao Corporation.
Perilla extract preparation and diet composition
To prepare the perilla extract, 5 L of SP-61509(P) (Saneigen, Osaka, Japan), the steam-distilled product of the leaf of green perilla, were added to 5 L of hexane for liquid-liquid extraction. The water layer was extracted twice, using 2 L of hexane each time, and the product evaporated to obtain a concentrated perilla extract with the following composition: PCHO (79.0%, w/w), limonene (3.7%) and peril alcohol (0.9%). The perilla extract was added to the diet. The control diet consisted of: 5% corn oil, 20% casein, 66.5% starch, 4% cellulose, 3.5% mineral and 1% of vitamin by weight. The perilla extract-containing diet consisted of: 5% corn oil, 20% casein, 66% starch, 4% cellulose, 3.5% mineral mix, 1% vitamin and 0.5% of perilla extract by weight.
Animal experiments
Experiment 1
SHRs were randomly allocated to two groups, the control group and the perilla extract diet group, with eight animals in each group. Animals were fed their respective diets for 2 weeks, after which cystometry was carried out as follows. Animals were anesthetized using 30 mg/kg of intraperitoneal pentobarbital sodium. The bladder was exposed and incised at the dome. A polyethylene catheter (PE50; Nippon Becton Dickinson, Tokyo, Japan) was inserted into the dome and fixed with silk threads. The other side of the polyethylene catheter was tunneled subcutaneously and fixed to the back of the neck. After surgery, each animal was caged individually. Intravesical pressure was measured in conscious animals 2 days post-surgery. The polyethylene catheter was connected to the transducer (Utah Medical Products, Midvale, UT, USA) and the syringe pump (Kd Scientific, Holliston, MA, USA). During cystometry, each animal was maintained in a Bollman cage, with the volume of urine measured using an electromagnetic scale (GX-400; Kensei, Ibaraki, Japan). No food or water was provided to the animals during cystometry. Room temperature saline was continuously infused into the bladder at a rate of 5.0 mL/h, using the syringe pump. Then, 20 min after the measurement, a 30-min data collection was completed from the time of first urination, to calculate micturition interval(s), micturition volume (mL), basal pressure (cmH 2 O), threshold pressure (cmH 2 O) and maximal pressure (cmH 2 O).
Experiment 2
Animals were again randomly allocated to two groups -the control group (n = 10) and the perilla group (n = 9). Animals were fed their respective diets, control or perilla extract, for 2 weeks. The animals were then euthanized by exsanguination under anesthesia with isoflurane. The bladder was isolated for analysis of gene expression and histology.
Reverse transcription polymerase chain reaction
A bladder tissue sample, approximately 5 mm 9 5 mm, was homogenized using zirconia beads (Bio Medical Science, Tokyo, Japan) and TissueLyser II (Qiagen, Hilden, Germany), and frozen at À80°C. Total RNA of the homogenized bladder and cell samples were extracted using the RNeasy Mini Kit (Qiagen). Complementary DNA was synthesized from 0.1 lg of total RNA using the High Capacity RNA-tocDNA Kit (Thermo Fisher Scientific, Rockford, IL, USA). Real-time PCR was carried out using Taqman probes and the Applied Biosystems 7500 Fast Real-Time PCR System (Thermo Fisher Scientific). The expression of GAPDH was used for normalization of the gene expression data. The following Taqman probes were used: NGF (Hs01113193_m1),
Enzyme-linked immunosorbent assay
The amount of UPK3A in the bladder was measured using an enzyme-linked immunosorbent assay kit for UPK3A (Cloud Clone, Houston, TX, USA). The concentration of proteins in the homogenized bladder was analyzed using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). The Viento AS multi-spectrophotometer (Dainippon Pharmaceutical, Osaka, Japan) was used to measure optical density. The amount of UPK3A was normalized to the concentration of proteins.
Immunohistochemistry
The isolated bladder was washed with PBS and embedded in an optimal cutting temperature compound, and the sample was frozen in liquid nitrogen. The frozen sample was cut into 8-lm thick sections and fixed in 4% paraformaldehyde at 4°C for 12 h. To inactivate the endogenous peroxidase, sections were soaked in methanol containing 0.3% hydrogen peroxide at room temperature for 30 min. After sections were washed with PBS, they were blocked with 5% rabbit serum at room temperature for 10 min and subsequently treated with mouse anti-uroplakin 3A antibody (1:40; Progen Biotechnik, Heidelberg, Germany) at room temperature for 1 h. Sections were again washed with PBS and subsequently treated with rabbit anti-mouse IgG-HRP (1:1000; Abcam, Cambridge, UK) at room temperature for 1 h. The UPK3A signal was detected using a DAB Peroxidase Substrate Kit (Vector Laboratories, Burlingame, CA, USA). Counterstaining was carried out using hematoxylin. Other frozen samples were cut and fixed, as described above, for hematoxylin and eosin staining for histological analysis.
Cell culture
Human urothelial cell line HT-1376 (American Type Culture Collection, Manassas, VA, USA), derived from a carcinoma of an elderly female bladder, was cultured in Dulbecco's modified Eagle's medium containing 10% of fetal bovine serum, 1 mmol/L sodium pyruvate, 2 lmol/L L-glutamine, 100 units/mL penicillin and 100 lg/mL streptomycin. NHBECs (Kurabo, Osaka, Japan) were cultured in UroLife ™ D Comp Medium (Kurabo). Cultures were maintained at 37°C in a humidified atmosphere of 5% CO 2 . Cells were seeded into twelve, 5.0 9 10 4 cell/mL, well plates. When cells had proliferated to a confluence of approximately 70%, PCHO or PCOOH was added to the culture medium for 1 h, followed by treatment with IL-1b for 4 h in HT-1376 and 8 h in NHBECs. Total RNA was extracted as described above. Cell viability was confirmed by Trypan blue staining.
Statistical analysis
Results were reported as the mean AE SEM. All data were analyzed with GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA). The significance between the two groups was tested using Student's t-test or Welch's t-test after the F-test. The significance was tested using a one-way ANOVA followed by Dunnett's test for multiple comparisons. A P < 0.05 was considered statistically significant.
Results
Perilla extract decreased the micturition frequency in SHRs
After the 2-week ingestion of the experimental diets, the body and bladder weight was not significantly different between groups (Table 1) . However, a significant 27% increase in micturition interval was observed in the perilla group, compared with the control group ( Fig. 1; Table 2 ; P = 0.03). The basal pressure was also significantly higher in the perilla group than in the control group (Table 2 ; P = 0.02). The micturition volume was not significantly changed, but a 20% increase was observed in the perilla group compared with that in the control group ( Fig. 1 ; Table 2 ; P = 0.15). No significant between-group differences in threshold pressure or maximal pressure were observed. These results show that perilla extract improves frequent urination without effects on the contraction of the detrusor muscle.
Perilla extract suppressed the expression of inflammatory cytokines and Trpv1 in the bladder
The expression of Ngf, Tnfa, Il1b and Trpv1 was significantly lower in the perilla than in the control group (Fig. 2) : Ngf, by 27% (P = 0.01); Tnfa, 48% (P = 0.004); Il1b, 83% (P = 0.001); and Trpv1, 37% (P < 0.001). Therefore, these results suggest that perilla extract suppresses inflammation and might regulate the function of TRPV1 in the bladder.
Perilla extract promoted the expression of UPK3A and maintenance of the urothelium
The level of UPK3A, the urothelial barrier molecule, was 40% higher in the perilla than in the control group ( Fig. 3a ; P = 0.007). In immunohistochemical analysis, although the expression of UPK3A was partly negative in the control group, a negative expression of UPK3A was rare in the perilla group (Fig. 3b,c) . The urothelium in the control group was thin or defective, but was almost completely intact in the perilla group (Fig. 3d,e) .
PCHO suppressed the induction of inflammation-related genes by IL-1b in HT-1376 and NHBECs
HT-1376 was treated with IL-1b for 4 h, as the serum level of IL-1b is high among patients with OAB. 14 The expression of NGF and TNFa was significantly increased after the addition of IL-1b ( Fig. 4 ; P < 0.05). In contrast, pretreatment 1 h before the addition of IL-1b with PCHO, which is the main component in perilla extract, or PCOOH, which is the final metabolite of PCHO, 15 suppressed the induction of NGF and TNFa in HT-1376 ( Fig. 4a,c ; P < 0.05). NHBECs were treated with IL-1b for 8 h and low-dose PCHO or PCOOH, because the response to IL-1b was slower and the sensitivity to perilla-related molecules was higher than that of HT-1376. Pretreatment 1 h before the addition of IL-1b with PCHO or PCOOH suppressed the induction of NGF and TNFa in NHBEC ( Fig. 4b,d ; P < 0.05). No significant difference in cell viability was observed.
Discussion
To our knowledge, this is the first report regarding the benefit of perilla extract in improving frequent urination in an animal model of spontaneous OAB. The improvement in frequent urination was accompanied by an increased expression of the barrier-related molecule, UPK3A, and a decreased expression of inflammation-related molecules. Perilla extract significantly increased the micturition interval in SHRs, indicating that perilla improves frequent urination without a significant effect on maximal pressure, which serves as an indicator of detrusor contraction. Atoropine, which suppresses detrusor contraction through an inhibition of muscarinic receptors, decreases maximal pressure. 16 These findings show that perilla extract suppresses bladder afferent activity without suppressing detrusor contraction, which is the efferent pathway of the micturition reflex. Treatment of OAB without decreasing the maximal pressure is necessary to improve urinary output in elderly men who frequently have a bladder outlet obstruction, such as benign prostatic hyperplasia. 17 Therefore, perilla extract could be effective for the treatment of OAB in elderly men, improving bladder function without suppressing contraction of the detrusor muscle. It should be noted that perilla extract significantly increased basal pressure, but the mechanisms underlying this increase are unknown. Values are reported as the mean AE SEM. Significant difference from the control group, *P < 0.05. 2 Relative expression of (a) Ngf, (b) Tnfa, (c) Il1b and (d) Trpv1 in the bladder after 2-week feeding using the control diet (n = 10) and the perilla extract-containing diet (n = 9). The amount of each mRNA was normalized to Gapdh mRNA levels and expressed relative to the control group. Values are presented as the mean AE SEM. Significant difference from the control group: *P < 0.05, **P < 0.01 and ***P < 0.001.
The detailed mechanisms of OAB have not been fully elucidated to date. However, inflammation of the bladder has been associated with OAB, similar to IC, which is a chronic inflammatory disorder of the bladder.
2-6 A highly significant increase in mast cell infiltration in the bladder 3 and serum Creactive protein 18 was observed in patients with OAB compared with healthy individuals. In addition, chronic inflammation was apparent in the urothelium and suburothelium in approximately 60% of patients with OAB.
2 These reports indicate that bladder inflammation is often observed in OAB similar to IC. In the present study, perilla extract decreased the expression of Ngf, TNFa and Il1b in the bladders of SHRs. Additionally, perillaldehyde and perillic acid suppressed the induction of NGF and TNFa by IL-1b in vitro. These findings confirm that perilla extract, whose main component is PCHO, is effective in suppressing inflammation of the bladder.
The urothelium is the most effective barrier of any biological membrane. 19 This barrier function is provided by the apical membrane of the surface layer of the urothelium. 20 Urothelial plaques, composed of UPK, play an important role in the barrier function of the urothelium. 21 In UPK3A knockout mice, urothelial plaques were destroyed and the barrier function of the urothelium decreased. 22 A previous study showed that the expression of UPK1B and UPK3A was decreased in patients with OAB compared with healthy individuals. 3 In contrast, no difference in the expression of ZONULA OCCLUDEN-1, which is a component of tight junctions in the urothelium, was observed between patients with OAB and healthy individuals. 23 The absence of an effect of UPK3A on the tight junctions of the urothelium was confirmed using UPK3A knockout mice. 24 These findings suggest that the decreased barrier function associated with OAB is related to the urothelial plaques, not to the intercellular barriers.
Perilla extract might suppress inflammation of the bladder and improve the barrier function of the urothelium. The analysis of the bladder in SHRs showed that the urothelium was thin or defective, which reduces UPK3A levels, as UPK3A is expressed in the apical membrane of the surface layer of the urothelium, 25 and therefore, its barrier function was also partly impaired. 26 Previous studies have shown a relationship between inflammation of the bladder and a loss of urothelial barrier function as a result of deletion of UPK3A in patients with IC.
3,5 Decreased expression of UPK3A and UPK1B was also reported in patients with OAB, although the level was less severe than that in patients with IC.
3 Rebamipide, a mucosal protective agent, has been shown to suppress frequent urination, increase the expression of UPK3A and decrease the expression of inflammatory cytokines in IC model rats. 26 These studies show that enhancing the urothelial barrier improves bladder inflammation. Perilla extract also increased the expression of UPK3A and supported the urothelium. Therefore, perilla extract could suppress the infiltration of urine into the bladder, which would indirectly improve inflammation by enhancing the urothelial barrier.
Perilla extract suppressed the expression of Trpv1 and inflammatory cytokines, such as Il1b and Ngf. TRP channels are associated with bladder function.
7-9 TRPV1 is mainly expressed in the sensory nerves of the bladder, and partly expressed in the urothelium and detrusor muscle. 27 A study using TRPV1 knockout mice showed that TRPV1 regulated bladder function and mechanically evoked signaling.
7 IL-1b and NGF promoted the expression of TRPV1. 28, 29 The bladders of patients with OAB showed chronic inflammation and increased expression of TRPV1.
2,8,9 Therefore, the high expression of inflammatory cytokines and chronic inflammation could promote the expression of TRPV1 and might induce OAB. In this regard, perilla extract would improve frequent urination by suppressing the induction of Trpv1 through IL-1b and NGF. Furthermore, the threshold value of TRPV1 was lowered in the presence of inflammatory cytokines. 30 These studies, taken together, raise the possibility that inflammation reduces the urothelial barrier function and induces urinary urgency by lowering the threshold of TRPV1. Perilla extract might improve OAB by reducing inflammation and preventing a lowering of the threshold of TRPV1, and, consequently, suppressing urinary urgency.
Some issues remain to be investigated in future research. Decreased expression of UPK and inflammation are characteristics of OAB 2,3,18 that are similar to those of IC, 3,5 but urothelial defects in patients with OAB have not been reported. Further research involving histological analysis of the urothelium in patients with OAB and investigating the effects of perilla in other animal models with urothelial defects would strengthen our predicted mechanisms of perilla extract. Furthermore, perilla extract increased the micturition interval without increasing the micturition volume. A precise measurement of the residual volume is required to investigate the effects of perilla on voiding efficiency.
In summary, we showed, for the first time, that perilla extract improves frequent urination in SHRs by enhancing the urothelial presence and providing anti-inflammatory effects. These effects of perilla extract might be relevant in alleviating OAB by suppressing bladder afferent activity. Perilla is expected to have beneficial effects in the treatment of human OAB.
